Allogene Therapeutics Launches CAR T Together™ Initiative Focused on Accelerating Development and Clinical Trial Recruitment for “Off-The-Shelf” Allogeneic Cell Therapy Investigational Products
“Many of the physicians who are part of CAR T Together here and behind the scenes were critical in advancing autologous CAR T therapies. These first-generation CAR Ts transformed how we treat certain difficult-to-treat cancers, but the arduous, individualized manufacturing process and complex supply chain have made it hard for drugmakers to keep up with growing demand,” said David Chang, M.D., Ph.D., President, CEO and Co-Founder of Allogene. “This collaboration aims to hasten our efforts to develop an allogeneic CAR T option with the potential to overcome these barriers and significantly expand patient access.”
Share:
More News
“We are encouraged by the progress of our clinical trial and remain focused on our goal to develop innovative therapies that can address glioblastoma and other cancers. Although we are unable to provide detailed information at this stage, we are excited about the continued advancement of this important program,” said
“We are disappointed in the outcome of the RELATIVITY-098 trial and that LAG-3 inhibition in the adjuvant setting did not lead to the same improved efficacy outcomes seen in advanced melanoma,” said Jeffrey Walch, M.D., Ph.D., vice president, Opdualag global program lead, Bristol Myers Squibb. “Patients whose tumors are completely
Ahsan Arozullah, M.D., M.P.H., Senior Vice President, Head of Oncology Development, Astellas said, “The combination of enfortumab vedotin and pembrolizumab was the first approval to offer an alternative to platinum-containing chemotherapy, which had been the standard of care for first-line locally advanced or metastatic urothelial cancer for decades. We are
“U.S. FDA has accepted for review the resubmission of the BLA for linvoseltamab for the treatment of adult patients with relapsed/refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy or those who received three prior lines of therapy and are refractory to the last
